Global Medical REIT (GMRE) AI Stock Analysis

• Market Cap: $632.05M
• Dividend Yield: 8.42%
• Average Volume (3M): 199.43K
• Price to Earnings (P/E): 97.4
• Beta (1Y): 0.72
• Revenue Growth: 0.90%
• EPS Growth: N/A
• Country: US
• Employees: 26
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Healthcare Facilities
• EPS (TTM): -0.05
• Shares Outstanding: 13,407,409
• 10 Day Avg. Volume: 317,980
• 30 Day Avg. Volume: 199,431
• PEG Ratio: -4.05
• Price to Book (P/B): 4.77
• Price to Sales (P/S): 18.39
• P/FCF Ratio: -101.51
• Enterprise Value/Market Cap: 2.03
• Enterprise Value/Revenue: 8.85
• Enterprise Value/Gross Profit: 12.93
• Enterprise Value/Ebitda: 13.16
• 1Y Price Target: $42.50
• Price Target Upside: 29.69% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4

• Rating: 60 Neutral
• Price Target: $38.00 ▲(15.96% Upside)

Global Medical REIT's overall score reflects strong financial performance and strategic growth initiatives. However, high valuation metrics and challenges such as dividend reduction and credit facility renewal weigh on the score. The technical analysis suggests a neutral market position, while the attractive dividend yield provides some support.

Positive Factors

Strong Revenue Growth

Consistent revenue growth indicates effective business operations and increasing demand for GMRE's healthcare facilities, supporting long-term financial health.

Operational Efficiency

High gross profit margin demonstrates GMRE's ability to manage costs effectively, ensuring sustainable profit generation and competitive positioning in the healthcare REIT sector.

Portfolio Acquisitions

Strategic acquisitions with high cash yields enhance GMRE's asset base and income potential, supporting long-term growth and portfolio diversification.

Negative Factors

Dividend Reduction

Dividend reduction may signal cash flow challenges or strategic reallocation of resources, potentially impacting investor sentiment and income expectations.

Credit Facility Renewal

Upcoming credit facility renewal poses a refinancing risk, which could affect GMRE's financial flexibility and cost of capital in the medium term.

Low Net Profit Margin

Low net profit margin indicates potential inefficiencies or high costs, which could limit profitability and shareholder returns if not addressed.

Global Medical REIT Business Overview & Revenue Model

Company Description

Global Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.

How the Company Makes Money

Global Medical REIT generates revenue primarily through lease agreements with healthcare providers who occupy its medical facilities. The company enters into long-term leases, often with built-in rent escalations, providing a stable and predictable income stream. Key revenue streams include rental income from these leases and potential additional revenue from property management services. GMRE may also benefit from partnerships with healthcare systems and providers, which can enhance its portfolio and occupancy rates. The company's focus on essential healthcare properties helps mitigate risks associated with economic downturns, as demand for medical services tends to remain stable regardless of broader economic conditions.

Global Medical REIT Financial Statement Overview

Summary

Global Medical REIT shows strong revenue growth and operational efficiency with high gross and EBIT margins. The balance sheet is stable with a robust equity base and no debt, enhancing financial stability. However, low net profit and return on equity indicate areas for improvement in profitability.

Income Statement

Global Medical REIT has shown a consistent increase in total revenue over the years, indicating growth in its operations. The Gross Profit Margin is strong at 99.88%, reflecting efficient cost management. However, the Net Profit Margin is low at 0.58%, suggesting high operating and non-operating expenses. The EBIT and EBITDA margins are robust at 78.94%, showing operational efficiency.

Balance Sheet

The company has a solid equity base, with an Equity Ratio of 42.52%, indicating a strong reliance on equity financing. The absence of debt in the latest year is a positive sign, reducing financial risk. However, Return on Equity is low at 0.15%, indicating limited returns to shareholders.

Cash Flow

The Operating Cash Flow to Net Income Ratio is high at 86.36, showing strong cash generation relative to net income. Free Cash Flow has grown significantly, indicating improved liquidity and the ability to reinvest in the business. The Free Cash Flow to Net Income Ratio is also favorable at 86.36.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	145.01M	138.41M	140.93M	137.28M	115.94M	93.73M
Gross Profit	99.27M	109.16M	112.85M	112.09M	100.45M	82.86M
EBITDA	97.53M	91.47M	111.64M	96.49M	84.00M	53.00M
Net Income	10.29M	6.63M	20.61M	-5.23M	-2.07M	-20.61M
Balance Sheet
Total Assets	1.30B	1.26B	1.27B	1.39B	1.26B	1.10B
Cash, Cash Equivalents and Short-Term Investments	6.58M	6.82M	26.40M	4.02M	7.21M	5.51M
Total Debt	732.70M	653.59M	618.91M	694.12M	571.73M	586.58M
Total Liabilities	771.94M	700.57M	661.89M	744.20M	625.91M	643.15M
Stockholders Equity	503.20M	534.13M	583.58M	632.98M	622.78M	444.81M
Cash Flow
Free Cash Flow	-52.47M	-25.07M	58.39M	-79.66M	-132.69M	-184.27M
Operating Cash Flow	71.24M	70.05M	68.44M	76.54M	68.97M	34.52M
Investing Cash Flow	-111.46M	-45.94M	67.62M	-137.25M	-194.66M	-223.67M
Financing Cash Flow	41.63M	-21.89M	-143.79M	62.41M	127.70M	192.72M

Global Medical REIT Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 32.77
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMRE, the sentiment is Negative. The current price of 32.77 is below the 20-day moving average (MA) of 35.46, below the 50-day MA of 34.67, and below the 200-day MA of 35.55, indicating a bearish trend. The MACD of -0.73 indicates Positive momentum. The RSI at 35.22 is Neutral, neither overbought nor oversold. The STOCH value of 12.35 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GMRE.

Global Medical REIT Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STRW	73 Outperform	$154.35M	19.75	51.91%	4.88%	24.72%	30.05%
SILA	71 Outperform	$1.34B	34.37	2.71%	6.56%	0.43%	58.57%
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
UHT	63 Neutral	$533.88M	29.73	10.08%	7.67%	0.14%	-0.76%
GMRE	60 Neutral	$632.05M	97.38	1.94%	8.42%	0.90%	―
DHC	59 Neutral	$1.06B	―	-14.32%	0.91%	4.29%	18.89%
CHCT	52 Neutral	$426.07M	―	-2.22%	12.48%	2.96%	-877.53%

Global Medical REIT Corporate Events

Global Medical REIT Appoints New CEO Mark O. Decker

On June 20, 2025, Global Medical REIT announced the transition of Jeffrey M. Busch from his role as Chief Executive Officer and President, effective June 23, 2025. Mark O. Decker, Jr. was appointed as the new CEO and President, bringing extensive experience in real estate investment and management. This leadership change is part of the company’s strategic efforts to enhance shareholder value and guide portfolio management and growth initiatives.